Skip to main content
. 2022 Oct 10;13(4):1771–1785. doi: 10.1016/j.apsb.2022.10.007

Figure 5.

Figure 5

The molecular mechanisms of compound 12 in anti-ischemia. (a) RNA-seq analysis of differential genes in pMCAO rat brains tissues (n = 5). 119 differential genes were identified between the vehicle group and compound 12 group. (b) 57 genes were up-regulated and 62 genes were down-regulated after compound 12 treatment. (c) 99 genes with opposite trends in the intersection of vehicle group versus sham group and vehicle group versus compound 12 group. (d) Gene enrichment analysis (GSEA) indicated antioxidant related pathway, including oxidoreductase activity; oxidoreductase activity (acting on the CH–OH group of donors); oxidoreductase activity (acting on the CH–CH group of donors); glutathione peroxidase activity; glutathione transferase activity and glutathione binding. (e) The level of Aifm3 mRNA in RNA-seq results. (f) compound 12 increased Aifm3 mRNA level by Q-PCR verification (n = 8). (g–h) compound 12 reversed the down-regulation of Aifm3 protein expressions in pMCAO rat brains (n = 3). (i) compound 12 protected OGD/R-induced neuronal injury (n = 4). (j–k) compound 12 elevated Aifm3 protein levels after OGD/R injury (n = 3). Data were shown as mean ± SEM, #P < 0.05, ###P < 0.001 vs. the sham group or control group, ∗P < 0.05 vs. the vehicle group or model group.